NCT00356889View on ClinicalTrials.gov

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

June 30, 2010

Conditions
Cholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderGastrointestinal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally, 150 mg, once daily.

BIOLOGICAL

bevacizumab

Given IV, 5mg/kg on days 1 and 15 every cycle

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00356889 - Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors | Biotech Hunter | Biotech Hunter